Pharmnxt Ekuse Profile
Key Indicators
- Authorised Capital ₹ 3.60 Cr
as on 17-11-2024
- Paid Up Capital ₹ 3.60 Cr
as on 17-11-2024
- Company Age 3 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.50 Cr
as on 17-11-2024
- Revenue 3560.82%
(FY 2023)
- Profit -2586.28%
(FY 2023)
- Ebitda -6792.91%
(FY 2023)
- Net Worth -35.12%
(FY 2023)
- Total Assets 77.94%
(FY 2023)
About Pharmnxt Ekuse
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.60 Cr and a paid-up capital of Rs 3.60 Cr.
The company currently has active open charges totaling ₹3.50 Cr.
Ankush Kapoor, Sachin Joshi, and Nandkumar Thakare serve as directors at the Company.
- CIN/LLPIN
U29308MH2021PTC372043
- Company No.
372043
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pharmnxt Ekuse?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankush Kapoor  | Director | 23-Nov-2021 | Current |
| Sachin Joshi | Director | 23-Nov-2021 | Current |
| Nandkumar Thakare | Director | 23-Nov-2021 | Current |
Financial Performance of Pharmnxt Ekuse.
Pharmnxt Ekuse Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 3560.82% increase. The company also saw a substantial fall in profitability, with a 2586.28% decrease in profit. The company's net worth observed a substantial decline by a decrease of 35.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmnxt Ekuse?
Unlock access to Pharmnxt Ekuse's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Pharmnxt Biotech LlpActive 7 years 6 monthsAnkush Kapoor, Sachin Joshi and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Aug 2023 | ₹3.50 Cr | Open |
How Many Employees Work at Pharmnxt Ekuse?
Pharmnxt Ekuse has a workforce of 14 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmnxt Ekuse, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmnxt Ekuse's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
